Nephrolithiasis against type 2 diabetes mellitus: on the effect of hypoglycemic therapy on lithogenesis

Hypoglycemic therapy over the past 20 years has expanded considerably with the use of new classes of more effective and safer medicines. Alongside the aging of the general population, the survival of diabetic subjects has significantly increased, thus exposing them to a greater risk of developing co-morbidities. This represents a challenge for the diabetologist, who must acquire ever broader concepts for the management of a complex and multi-organ disease. We report the case of a 72-year-old woman with type 2 diabetes mellitus and pulmonary adenocarcinoma of the right upper lobe with brain and bone metastases who, subjected to innovative and integrated treatments agreed between specialists of different disciplines, is still alive and free of cancer symptoms 23 months after diagnosis (Diabetology)

Download Full-text

Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment

Scientific Reports ◽

10.1038/s41598-020-72035-1 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Xiaoyu Sun ◽

Meihui Li ◽

Li Xia ◽

Zhaohui Fang ◽

Shenjun Yu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Rrna Gene ◽

Ralstonia Pickettii ◽

Health Group ◽

Significant Difference ◽

Rrna Gene Sequencing ◽

Hypoglycemic Therapy

Abstract We aimed to explore the effects of type-2 diabetes mellitus (T2DM) and hypoglycemic therapy on the salivary microbiome in periodontitis patients and identify the potential salivary micro-biomarker for the early warning of T2DM. Saliva samples were collected from healthy individuals (Health), periodontitis patients (P), T2DM patients, periodontitis patients with T2DM (DAP), and DAP patients treated with Metformin (Met). Samples were determined by16S rRNA gene sequencing. 29 phyla, 322 genera, and 333 species of salivary microbiome were annotated. Compared to the Health group, the P and DAP group showed a significantly higher diversity of saliva microbiota, while the T2DM and Met group had no significant difference in microbial abundance but showed a trend of increasing diversity. Other than well-known periodontitis-inducing pathogens, the proportion of Prevotella copri, Alloprevotella rava, and Ralstonia pickettii, etc. were also significantly increased in periodontitis patients with or without T2DM. After effective glycemic control, the abundance of Prevotella copri, Alloprevotella rava, Ralstonia pickettii, etc. decreased in periodontitis patients with companion T2DM. The accuracies of the classification models in differentiating Health-vs.-P, DAP-vs.-P, and T2DM-vs.-P were 100%, 96.3%, and 98.1%, respectively. Hypoglycemic therapy could reconstruct the saliva microbiota and hence improve the localized conditions of diabetes patients with periodontitis.

Download Full-text

Quality of Life (QOL) and Health Utility (UT) in Patients with Type 2 Diabetes Mellitus (DM2) Receiving Different Oral Hypoglycemic Therapy in a Real-World Setting

Value in Health ◽

10.1016/j.jval.2016.09.1906 ◽

2016 ◽

Vol 19 (7) ◽

pp. A678

Author(s):

T Ionova ◽

T Nikitina ◽

A Rodionova ◽

K Kurbatova

Keyword(s):

Quality Of Life ◽

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Real World ◽

Health Utility ◽

Real World Setting ◽

Hypoglycemic Therapy

Download Full-text

Clinical significance of the ADVANCE study for a practitioner: Possibility to treat and prevent complications of type 2 diabetes mellitus

Problems of Endocrinology ◽

10.14341/probl20095556-9 ◽

2009 ◽

Vol 55 (5) ◽

pp. 6-9

Author(s):

V N Shishkova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Blood Glucose ◽

Blood Glucose Level ◽

Glucose Level ◽

Advance Study ◽

Safe Control ◽

Hypoglycemic Therapy

ADVANCE is a multicentre placebo-controlled randomized trial undertaken to investigate effects of intensive decrease of blood pressure and blood glucose level on the development of major micro- and macrovascular complications in patients with type 2 diabetes mellitus. Patients included in the study designed to evaluate results of intense glycemic control were given glyclazide modified release (diabeton MR) as the basic treatment. The main results of ADVANCE indicate that intense hypoglycemic therapy with the use of diabeton MR allows for efficient and safe control of blood glucose level with the reduction of the mean HbA1c level to 6.5% or less. Also, this treatment significantly decreases the risk of severe diabetic complications by 10% including nephropathy and proteinuria (by 21% and 30% respectively).

Download Full-text

Effect of alpha-lipoic acid on arterial stiffness parameters in type 2 diabetes mellitus patients with cardiac autonomic neuropathy

Endocrine Regulations ◽

10.2478/enr-2021-0024 ◽

2021 ◽

Vol 55 (4) ◽

pp. 224-233

Author(s):

Victoria A. Serhiyenko ◽

Ludmila M. Serhiyenko ◽

Volodymyr B. Sehin ◽

Alexandr A. Serhiyenko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Arterial Stiffness ◽

Lipoic Acid ◽

Augmentation Index ◽

Cardiac Autonomic Neuropathy ◽

Alpha Lipoic Acid ◽

Hypoglycemic Therapy

Abstract Objective. Significantly underdiagnosed, diabetes-associated cardiac autonomic neuropathy (CAN) causes a wide range of cardiac disorders that may cause life-threatening outcomes. This study investigated the effects of alpha-lipoic acid (ALA) on arterial stiffness and insulin resistance (IR) parameters in type 2 diabetes mellitus (T2D) patients and definite CAN. Methods. A total of 36 patients with T2D and a definite stage of CAN were recruited. This investigation was carried out on two separate arms: traditional hypoglycemic therapy (n=18, control) and ALA (n=18) 600 mg in film-coated tablets/q.d. in addition to traditional hypoglycemic therapy. The duration of the study was three months. Results. In subjects with T2D and definite stage of СAN, treatment with ALA resulted in a significant decrease of glucose, immunoreactive insulin concentration, and Homeostasis Model Assessment (HOMA)-IR (HOMA-IR) parameters; pulse wave velocity (PWV), aorta augmentation index (AIxao) during the active period of the day and decrease of PWV, AIxao, and brachial augmentation index during the passive period of the day compared with the results, obtained in the control group. Therefore, the administration of ALA to patients with T2D for three months promotes the improvement of glucose metabolism and arterial stiffness parameters. Conclusions. In patients with T2D and definite stage of СAN treatment with ALA improved HOMA-IR and arterial stiffness parameters. These findings can be of clinical significance for the complex treatment of diabetes-associated CAN.

Download Full-text